---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-042231"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:41:33.691378+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data

## Summary
- Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.
- Cohort 4 RA data: abiprubart 400 mg SC monthly showed DAS28-CRP LS mean difference -0.58 vs placebo (p=0.109, not significant).
- Statistically significant ~40% reduction in Rheumatoid Factor in Cohort 4 (p=0.0003); pooled analysis DAS28-CRP diff -0.52 (nominal p=0.010).
- Abiprubart development in Sjogren's fully funded through Phase 3; company expects to remain cash flow positive annually.

## SEC filing metadata
- accession: 0001104659-24-042231
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/0001104659-24-042231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/tm249997d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-042231
- JSON: https://secwatch.observer/filing/0001104659-24-042231.json
- Plain text: https://secwatch.observer/filing/0001104659-24-042231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.